Subject matter experts (SMEs) from BioPhorum’s member companies have joined together to form a truly cross-functional team, focusing on the challenge of industry adoption of ILM/RTR, bringing diverse perspectives from across the industry. Most of the SMEs are involved in at least one of the other BioPhorum workstreams dedicated to the advancement of specific building blocks that will enable the adoption of ILM/RTR. Each building block is valuable in its own right and will represent significant change. Together, they will allow biopharmaceutical manufacturers to reach the ulitmate goal of automated process control and automatic release
The priority for the program is to support the business requirements for adoption, and the team has now developed an operational vision. Taking a technology-agnostic approach, the vision articulates the beginning, middle and aspirational future states for adoption and a high-level sequence for implementation of ILM/RTR. This is important as it starts to describe how a factory of the future will operate and how organizations might stage their investment to get there from their current state.